Morton Grove Pharmaceuticals, Inc. FDA Inspection Record

FEI 1420913 · Inspections, Form 483s, warning letters and import refusals

Morton Grove Pharmaceuticals, Inc. is an FDA-inspected facility (FEI 1420913) located in Morton Grove, IL, US. RegDataLab tracks 6 FDA inspections and 2 compliance actions at this facility.

What FDA found at this site

Latest inspection
Feb 5, 2016: Official Action Indicated (OAI)
Inspections on record
6 (1 OAI, 4 VAI, 1 NAI)
Last OAI inspection
Feb 5, 2016
Warning letters
1 listed by FDA for this FEI, latest Feb 17, 2017
Form 483 and inspection documents
1 in FDA's reading room
Recalls as the recalling firm
13, latest Feb 21, 2022
Import refusals
2

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Feb 5, 2016Official Action Indicated (OAI)No citations listed
Mar 26, 2014Voluntary Action Indicated (VAI)No citations listed
Apr 12, 2011Voluntary Action Indicated (VAI)SOPs not followed / documented (21 CFR 211.100(b))
Investigations of discrepancies, failures (21 CFR 211.192)
Approval and review of procedures (21 CFR 211.100(a))
Procedures to be written and followed (21 CFR 211.198(a))
Mar 24, 2010Voluntary Action Indicated (VAI)Identity Testing of Each Component (21 CFR 211.84(d)(1))
Valid stability test methods (21 CFR 211.166(a)(3))
Complaint Handling Procedure (21 CFR 211.198(a))
Sep 17, 2009No Action Indicated (NAI)No citations listed
Mar 17, 2009Voluntary Action Indicated (VAI)Test method modification records do not include (21 CFR 211.194(b))
Failure to meet specifications (21 CFR 314.81(b)(1)(ii))

Recalls

Showing the 10 most recent of 13 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Feb 21, 2022Class IID-0713-2022Dexamethasone Elixir, USP 0.5 mg/5 mL, Net: 8 fl oz (237 mL) bottle, Rx only, Manufactured…
Failed Impurities/Degradation Specifications: higher than permissible levels of unknown impurities were found in the drug product.
Sep 3, 2021Class IID-0814-2021Promethazine Syrup Plain, 6.25 mg/5 mL (Promethazine Hydrochloride Syrup, USP), 1 Pint… and 2 more products
CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms.
Dec 9, 2020Class IID-0174-2021Hydroxyzine Hydrochloride Oral Solution, USP (Syrup), 10 mg/5 mL, packaged in a) 4 fl oz…
Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total…
Sep 23, 2019Class IID-0130-2020Prednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, packaged in a 8 fl oz (237 mL)…
Failed Impurities/Degradation Specifications - failed specs for Prednisolone Impurity 14
Jul 24, 2018Class IID-1042-2018Prednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, 8 fl oz (237 mL) Bottle, Rx only…
Defective Container: Tamper Evident foil seal not completely intact.
Aug 10, 2017Class IID-1125-2017Amoxicillin and Clavulanate Potassium for Oral Suspension, USP, 250/62.5 mg per 5 mL, 100…
Presence of Foreign Substance: customer complaint of blue foreign material identified as a portion of a nitrile glove was discovered in…
Dec 15, 2015Class IIID-0571-2016Lindane Lotion, USP 1%, For External use Only, Rx Only, 2 fl oz (60 mL) bottle, MGP, NDC…
Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.
Oct 13, 2006Class IIID-400-7Prednisolone Sodium Phosphate Oral Solution, 5 mg/5 mL, 4 fl oz bottles, Rx only, NDC…
One individual unknown impurity level exceeds specification
Dec 2, 2005Class IID-069-6Prednisolone Oral Solution, USP 15 mg/5 mL (formerly Prednisolone Syrup, USP 15 mg/5 mL)…
Degradant/Impurity level exceeded specification requirements of not more than 0.50%.
Sep 13, 2004Class IID-278-4Phenytoin Oral Suspension, USP, 125 mg/5 mL, Morton Grove Pharmaceuticals, Inc., Morton… and 1 more product
Superpotent: Super-potency of the active ingredient

Form 483s and inspection documents

  • 483 on FDA.gov
    Issued Mar 26, 2014 (dates printed on the document). FDA listing date Jul 10, 2015. Published by FDA Jan 18, 2024.

FDA record score

15 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 17, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

14 records behind this number
RecordDatePoints x age weightAdds
Warning letter on FDA's dashboard, which does not show close-outsFeb 17, 201730 x 0.257.5
Class II recall D-0713-2022, this FEI as the recalling firmFeb 21, 20224 x 0.62.4
Class II recall D-0814-2021, this FEI as the recalling firmSep 3, 20214 x 0.251
Class II recall D-0174-2021, this FEI as the recalling firmDec 9, 20204 x 0.251
Class II recall D-0130-2020, this FEI as the recalling firmSep 23, 20194 x 0.251
Class II recall D-1042-2018, this FEI as the recalling firmJul 24, 20184 x 0.251
Class II recall D-1125-2017, this FEI as the recalling firmAug 10, 20174 x 0.251
Inspection classified OAIFeb 5, 201610 years or older, so it adds no points0
Inspection classified VAIMar 26, 201410 years or older, so it adds no points0
Inspection classified VAIApr 12, 201110 years or older, so it adds no points0
Inspection classified VAIMar 24, 201010 years or older, so it adds no points0
Inspection classified VAIMar 17, 200910 years or older, so it adds no points0
Class II recall D-069-6, this FEI as the recalling firmDec 2, 200510 years or older, so it adds no points0
Class II recall D-278-4, this FEI as the recalling firmSep 13, 200410 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 17, 2026Newest record Nov 9, 2026Current
Inspection citationsNov 17, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 17, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 17, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 17, 2026Newest record Nov 16, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Morton Grove Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Morton Grove Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Morton Grove Pharmaceuticals, Inc.
Location
Morton Grove, IL (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.